Xtant Medical Holdings, Inc. (XTNT) Stock Price & Analysis
Xtant Medical Holdings, Inc. (XTNT) — MoonshotScore 25/100 (Weak band), calculated Nov 22, 2026. Price $0.21 (-2.82%), as of the Nov 20, 2026 trading session; market cap $29.5M.
Educational signal · not a buy or sell recommendation · How to read this
Xtant Medical Holdings, Inc. · XTNT
Xtant Medical Holdings, Inc. specializes in regenerative medicine products and medical devices for orthopedic and neurological surgeons. The company is headquartered in Belgrade, Montana, and operates both domestically and internationally.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Xtant Medical Holdings (XTNT)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fragile balance sheet and stalling growth. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Fair; Growth Durability: Fading; Momentum: Slipping.
- quarterly revenue $23M (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 4 of the last 8 reports
- Altman Z -3.27 · Piotroski F 2
Holding back: balance-sheet strain, soft growth, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 24 | Weak | |
| 24 | Weak | |
| 24 | Weak |
The score moved from 24 in the stored Nov 21, 2026 snapshot to 25 in the current publication computed Nov 22, 2026 (+1); the largest pillar moves were Momentum +3. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.21 | |
| Change on the day | -2.82% | |
| 52-week range | $0.17 – $0.84 | |
| Market capitalisation | $29.5M | — |
| Price / earnings (trailing) | 35.23 | |
| Shares traded on the day | 257.1K |
Price & events
Other perspectives
Council score for Xtant Medical Holdings (XTNT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is Xtant Medical Holdings (XTNT), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Xtant Medical Holdings, Inc. (XTNT) is the company analyzed here. It employs 151 people and is led by Sean E. Browne. In Q2 FY2026 it reported revenue of $23M and net income of -$9M. The market values it at $29.5M.
What do the latest results show for Xtant Medical Holdings (XTNT)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $23M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $23M | -$9M | -$0.07 (diluted) |
| Q1 FY2026 | $21M | -$3M | -$0.02 (diluted) |
| Q4 FY2025 | $32M | $57,000 | $0.0004 (diluted) |
| Q3 FY2025 | $33M | $1M | $0.01 (diluted) |
What are the financial strengths and risks for Xtant Medical Holdings (XTNT)?
Short answer · as of
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z -3.27 · Piotroski F 2. Trailing ratios: ROE -23.5% · ROA -14.0% · current ratio 2.16 · earnings yield -29.1% · free-cash-flow yield -1.8%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -3.27 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-23.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Xtant Medical Holdings (XTNT)?
Short answer · as of
The stored analyst-target capture is expired, so a current target watchpoint is unavailable.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Xtant Medical Holdings compare with its peers?
Short answer
Xtant Medical Holdings's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $22.98 Nov 20, 2026 | $188M | 88 5-pillar Nov 22, 2026 | |
| $99.94 Nov 20, 2026 | $128B | 82 5-pillar Nov 22, 2026 | |
| $310.00 Nov 20, 2026 | $118B | 81 5-pillar Nov 22, 2026 | |
| $101.10 Nov 20, 2026 | $19.1B | 80 5-pillar Nov 22, 2026 | |
| $41.98 Nov 20, 2026 | $60.9B | 77 5-pillar Nov 22, 2026 | |
| $13.23 Nov 20, 2026 | $177M | 72 5-pillar Nov 22, 2026 | |
| $4.46 Nov 20, 2026 | $54.8M | 43 5-pillar Nov 22, 2026 | |
| $1.49 Nov 20, 2026 | $93.7M | 43 5-pillar Nov 22, 2026 | |
| $2.93 Nov 20, 2026 | $87.6M | 41 5-pillar Nov 22, 2026 | |
| $2.08 Nov 20, 2026 | $31.5M | 38 5-pillar Nov 22, 2026 | |
| $5.30 Nov 20, 2026 | $138M | 37 5-pillar Nov 22, 2026 | |
| $6.07 Nov 20, 2026 | $247M | 36 5-pillar Nov 22, 2026 | |
| Xtant Medical Holdings (XTNT) — this page | $0.21 | $29.5M | 25 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
- $1.00 – $1.00
- Last captured analyst target (expired, captured Nov 18, 2026)
- $1.00
- Last captured median analyst target (expired, captured Nov 18, 2026)
- $1.00
Historical target record · Captured · Capture expired; not a current watchpoint.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held XTNT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported XTNT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: XTNT Stock
These answers are editorial: 1 of these 9 answers is drawn from the XTNT research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for XTNT?
XTNT carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Xtant Medical Holdings, Inc. specializes in regenerative medicine products and medical devices for orthopedic and neurological surgeons.
Is XTNT a good stock to buy?
Stock Expert AI does not rate XTNT buy, sell or hold. Xtant Medical Holdings, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the XTNT stock price today?
The last price recorded for Xtant Medical Holdings, Inc. (XTNT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the XTNT price target?
The last analyst consensus price target we captured for Xtant Medical Holdings, Inc. (XTNT), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
What are the main risks for XTNT?
Xtant Medical Holdings, Inc. faces several risks, including regulatory challenges that could delay product approvals, intense competition from established medical device companies, and market fluctuations that may impact healthcare spending.
What are the key factors to evaluate for XTNT?
Xtant Medical Holdings, Inc. (XTNT) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. This trend is expected to drive growth in the orthopedic and neurological markets, aligning with Xtant's product offerings. Not financial advice.
How frequently does XTNT data refresh on this page?
XTNT's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven XTNT's recent stock price performance?
Xtant Medical Holdings, Inc. (XTNT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product portfolio with unique biomaterials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider XTNT overvalued or undervalued right now?
The trailing P/E of Xtant Medical Holdings, Inc. (XTNT) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 11 from Financial Modeling Prep (FMP), 7 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com